NCM
DMAC icon

Nantahala Capital Management’s DiaMedica Therapeutics DMAC Stock Holding History

Nantahala Capital Management’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-756,193
Closed -$3.21M – 116
2020
Q3 		$3.21M Buy
756,193
+6,193
+0.8% +$32.8K 0.1% 91
2020
Q2 		$5.2M Hold
750,000
– – 0.16% 83
2020
Q1 		$2.14M Buy
+750,000
New +$3.1M 0.08% 91

Other funds holding DMAC

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nantahala Capital Management's DMAC Position: Q4 2020 in Review

Nantahala Capital Management sold out of DiaMedica Therapeutics (DMAC) in Q4 2020, closing a stake of 756,193 shares — an estimated $3.21M sold.

Nantahala Capital Management first reported a position in DMAC in Q1 2020 and held it in 3 quarters. The position peaked at $5.2M in Q2 2020. 36 funds tracked by Wall St. Rank hold DMAC as of Q4 2020.

  • Nantahala Capital Management reported no remaining DiaMedica Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Nantahala Capital Management sold 756,193 DiaMedica Therapeutics shares in Q4 2020, an estimated $3.21M.
  • Nantahala Capital Management first reported a position in DiaMedica Therapeutics in Q1 2020 and held it in 3 quarters.
  • Nantahala Capital Management's DiaMedica Therapeutics position peaked at $5.2M in Q2 2020.
  • 36 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q4 2020.

Based on Nantahala Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.